Submitted:
28 September 2026
Posted:
29 September 2026
You are already at the latest version
Abstract
Background. The Naval Medical Research Center and Biopure Corporation developed the proposed Restore Effective SUrvival in Shock (RESUS) trauma trial of HBOC-201. A military research agreement, a planned field contingency, an investigational new drug application and permission to start a trial represent different steps. This review examines what the public record establishes about each step. Methods. We reviewed selected public records from 2003 to 2008: the RESUS agreement and amendment, a Department of Defense budget justification, an FDA advisory meeting notice and contemporaneous Biopure filings with the US Securities and Exchange Commission. We classified each action by actor, date and documented status. This is a focused historical review, not a systematic search or an evaluation of clinical efficacy. Results. The agreement assigned Navy and company roles and later included a conditional defense contingency provision for a possible request for 1,500 units. That provision did not itself authorize clinical use or establish delivery. NMRC submitted a RESUS investigational new drug application in June 2005, and FDA placed the proposed trial on clinical hold in July. An FDA advisory committee discussed the proposal in December 2006. Biopure reported an 11 to 8 vote, with one abstention, against proceeding with the design then proposed; the revised Phase 2 protocol remained on hold in 2007. A separate DoD budget line and subsequent preclinical supply arrangements document research activity, not battlefield deployment. Conclusion. The records trace RESUS from military research planning through IND submission, clinical hold, advisory review, revised protocol and preclinical product work. They do not establish that the proposed RESUS human trial began, that the contingency supply clause was executed, or that HBOC-201 received US authorization for operational military use.
Keywords:
RESUS
; military medicine
; historical review
; Naval Medical Research Center
; HBOC-201
; Hemopure
; clinical hold
; defense contingency
; regulatory history
Introduction
Military trauma care has a recurring timing problem: a casualty may need oxygen-carrying support before compatible donor blood and definitive hemorrhage control are available. HBOC-201 was investigated as one possible response to that gap. On 4 March 2003, the Naval Medical Research Center (NMRC) and Biopure Corporation entered a cooperative research and development agreement (CRADA) titled Restore Effective SUrvival in Shock. NMRC had authored the proposed prehospital trial protocol; Biopure provided the investigated product and manufacturing and development expertise [1].
The agreement was a research arrangement. This review asks which steps in the military development and regulatory pathway are documented as completed between 2003 and 2008, and which remained proposed or conditional. It follows the conceptual Article I on Precision Oxygen Therapeutics [10], while examining a narrower historical question. A related broad narrative review submitted separately to Preprints.org as manuscript 235133 surveys emergency and military development, product characterization and later physiological concepts. The present review concentrates on the decision record, including the IND and hold, the advisory sequence, a DoD budget entry and the limits of the defense contingency clause.
Methods
We examined selected public records that named RESUS or directly governed its development, from the 2003 agreement through the November 2008 update. The source set comprises the SEC-filed CRADA and Amendment 3 [1]; Biopure fiscal 2005 and 2007 annual reports [2,8]; a February 2007 DoD budget justification [3]; the FDA November 2006 advisory meeting notice [4]; SEC-filed company updates from February, July and August 2007 [5,6,7]; and the November 2008 Form 8-K [9]. The records were checked through 28 September 2026. This is a selected historical source set, not a systematic search of all government, company or trial files.
For each record we noted the date, issuing institution, stated or completed action and evidence limit. A signed agreement establishes contractual terms; an IND submission documents a request to investigate; a clinical hold prevents the proposed trial from starting as submitted; an advisory vote is a recommendation rather than FDA authorization; and a budget line does not by itself prove payment to the company. A future protocol, purchase or field supply described as expected was coded as a plan. Statements about FDA decisions that appear only in Biopure filings are attributed to Biopure. We did not have the complete IND correspondence, FDA decision letters, procurement receipts or RESUS patient data.
Results
The Agreement and the Proposed Financial Architecture
The original CRADA assigned scientific and administrative roles before there was an approved trauma protocol. Its initial schedule estimated $8,752,875 of Biopure contributions and $4,000,000 of NMRC contributions across fiscal years 2003 to 2006. The agreement explicitly described these amounts as estimates subject to FDA requirements and additional financing [1]. The figures therefore specify the design of the collaboration; they do not prove that either amount was ultimately spent.
Amendment 3 later shifted key responsibilities: NMRC would submit the IND and procure GMP material for the trial. A separate special term described possible contingency supply on a written NMRC request, subject to law and realistic production capacity, for military units totaling at least 10,000 personnel. The text used 1,500 HBOC-201 units as the corresponding quantity and set Biopure’s estimated total manufacturing, regulatory, administrative and distribution cost at no more than $650 per unit [1]. This is a conditional cost ceiling, not an invoice, an observed Navy purchase price, or proof of field delivery. The agreement separately stated a different pricing mechanism for future US government sales [1].
IND Submission, Clinical Hold and Advisory Review
Biopure reported that NMRC submitted the proposed RESUS IND in June 2005. FDA placed the protocol on clinical hold in July 2005. The fiscal 2005 report ascribed the hold primarily to FDA concerns about safety and the risk–benefit balance in the target trauma population, and said that the hold continued following a September 2005 response [2]. A government budget account later specified 8 July 2005 as the hold date and referred to concern about raised blood pressure and other potential adverse effects [3]. Neither account is a released FDA hold letter, which limits how precisely the agency’s reasoning can be reconstructed.
The FDA publicly announced a Blood Products Advisory Committee meeting for 14 December 2006 to discuss preclinical and clinical evidence for HBOC-201 and an NMRC-proposed emergency research study [4]. Biopure subsequently reported that the advisory committee voted 11 to 8, with one abstention, against proceeding with the proposed 1,100-patient Phase 2b/3 RESUS study as designed. The company reported interest among committee members in a smaller prehospital Phase 2 study [5,8]. The Federal Register notice independently verifies the meeting agenda and date, not the vote tally; the tally here remains explicitly attributed to Biopure. An advisory recommendation is distinct from an FDA authorization to begin a clinical trial.
NMRC submitted a revised Phase 2 protocol, according to a July 2007 Biopure letter [6]. In August 2007 the company reported that FDA had kept the revised protocol on clinical hold [7]. Its fiscal 2007 annual report likewise stated that the hold remained in the fourth quarter of 2007 and identified further FDA action, DoD authorization and participating hospitals’ institutional review boards as prerequisites [8]. We found no document in the defined corpus showing that the proposed RESUS study opened for enrollment under this protocol.
Budget Information, Service Roles and What the Amounts Measure
Biopure’s fiscal 2005 report stated that Congress had appropriated a cumulative $22.5 million to the Department of Defense for Hemopure-related trauma development, comprising $16 million to the Navy and $6.5 million to the Army [2]. The filing does not say that Biopure received that total. In a separate February 2007 Defense Acquisition Challenge Program justification, a RESUS line lists $0.332 million in fiscal 2006 and zero in the displayed fiscal 2007 to 2009 columns. That document names Air Force as the lead service for this particular budget entry, while its narrative recounts the NMRC submission, FDA hold and planned advisory review [3].
The Air Force label describes the lead service in a specific budget project. It does not displace NMRC’s role as sponsor of the proposed trial or establish a second completed clinical program. The $0.332 million budget line cannot simply be added to the company-reported $22.5 million or the CRADA’s estimates: the sources have different scopes, dates and accounting meanings. The budget justification itself says little program progress had occurred after the hold [3].
Preclinical Procurement and 2008 Proposals
Biopure’s fiscal 2007 annual report says that, in the fourth quarter of that year, the Navy agreed to buy Hemopure and seven modified formulations for preclinical testing. It also reports grants to eight institutions totaling more than $1.7 million for modification testing and projects approximately $1.6 million in proceeds to Biopure from the product sales [8]. The filing supplies evidence of an agreement for research materials and projected proceeds, but it does not establish the per-unit price of a completed purchase, the number of units delivered, or administration to patients.
In its November 2008 Form 8-K, Biopure said the Navy was expected to submit three protocols: a revised RESUS study requiring an exception from informed consent and still on hold, an operational military version termed Op RESUS that would involve prior consent, and a Phase 1b safety study combining Hemopure with a nitric oxide donor. The same filing states that Biopure continued to produce and ship “combination products” under its Navy agreement [9]. Shipment of unspecified combination research products is a more advanced status than a mere proposal. The filing does not link those shipments to the conditional 1,500-unit defense supply clause, provide delivered quantities, show administration under RESUS, or document operational deployment.
Documented Decision States
Table 1 records the most consequential transitions. The table separates what the cited document actually establishes from the additional step required to claim clinical or operational use.
Discussion
Read together, these records show a program with substantial institutional preparation but a constrained clinical path. The signed CRADA specifies who would develop the trial; the IND establishes that a proposal reached FDA; the hold and subsequent advisory review explain why the planned large trial could not be treated as an operational accomplishment. The 2007 and 2008 filings show that scientific development continued through protocol revision and modified-product work even while the RESUS clinical study remained on hold [1,2,3,4,5,6,7,8,9].
The findings also clarify a recurrent problem in accounts of military biomedical development. A proposed budget, an appropriation to DoD, a collaboration cost estimate, a projected company sales figure and a shipment all refer to money or goods, but they answer different questions. Likewise, a Navy-sponsored trial and an Air Force-led budget entry can appear in the same program history without showing that either service bought an operational stockpile. The public documents support a limited institutional map, not a complete procurement ledger [1,2,3,8,9].
The absence of documented completion or administration in this selected corpus is a limit of the record, not a demonstration that no activity occurred anywhere. In particular, the 2008 shipment statement prevents a categorical claim that no Navy-related material was supplied. What remains unsupported is the more specific assertion that the 1,500-unit contingency was executed or that the proposed RESUS trial administered HBOC-201 to enrolled patients [1,9]. Individual US expanded-access treatment for other indications and use in other countries should not be substituted for those RESUS-specific outcomes [5,8].
This historical analysis concerns Biopure’s HBOC-201 and the regulatory events of 2003 to 2008. It is not evidence of clinical efficacy of a future BHOC formulation, current Navy use, US marketing approval for Hemopure, or an endorsement by FDA or DoD. Contemporary research must independently characterize product-specific physiology, safety, relevant patient selection and the practical circumstances in which a therapy would be available.
Limitations
The sample is purposive and relies partly on company-authored statements filed with the SEC; those disclosures are contemporaneous primary records of what Biopure reported, not independent copies of FDA correspondence or DoD procurement files. We could confirm the 2006 advisory agenda in the FDA’s Federal Register notice, but did not obtain the committee transcript or minutes to verify the company-reported vote. The DoD budget document describes one project line rather than total program spending. We did not inspect complete IND correspondence, contract performance records, purchase orders, shipment receipts, site approvals or patient-level data. The analysis cannot assess the treatment’s benefits or harms or reconstruct the full cost of RESUS.
Conclusion
Between 2003 and 2008, RESUS moved from a signed Navy–industry research agreement to an IND under FDA clinical hold, an advisory review, a revised but still held Phase 2 protocol, preclinical formulation work and further proposed protocols. The original agreement’s $650 term was a conditional estimated cost ceiling for potential contingency supply; the available evidence does not establish that 1,500 units were purchased or deployed. Keeping each document at its actual decision stage yields a usable history of the program without converting plans, budget lines or research shipments into clinical or operational results.
Funding
The authors self-funded preparation of this review. No external funding was received for its preparation.
Ethics
This analysis uses publicly available historical records. It includes no new human participant data or intervention.
Data Availability Statement
Every primary document analyzed is publicly accessible through the direct links in References. Table 1 summarizes the extraction and the boundaries of each documentary claim; no new patient dataset was generated.
Use of Artificial Intelligence
OpenAI ChatGPT assisted with source organization, drafting and language editing. The authors remain responsible for the historical interpretation, source checking and final text.
Relationship to Other Manuscript
Article I introduces Precision Oxygen Therapeutics [10]. A broader historical review submitted to Preprints.org as manuscript 235133 discusses emergency and military development of HBOC-201 alongside product characterization and physiological interpretation. The present review analyzes the specific military and regulatory decision sequence and adds a separate examination of the DoD budget entry, the December 2006 advisory process and the 2007 revised protocol. The related manuscript and this overlap should be disclosed to the editors.
Conflicts of Interest
Carl W. Rausch and Bing-Lou Wong were professionally involved in Biopure Corporation and the oxygen therapeutic program discussed here. Archil Jaliashvili leads BHOC Therapeutics and has a current professional interest in oxygen therapeutics. These relationships may be relevant to the interpretation of the historical record.
References
- Naval Medical Research Center and Biopure Corporation. Restore Effective SUrvival in Shock cooperative research and development agreement NCRADA-NMRC-03-1497, signed 4 March 2003, including Amendment 3. SEC-filed exhibit. 2005. Available online: https://www.sec.gov/Archives/edgar/data/815508/000095013505005658/b56979bcexv99w1.htm.
- Biopure Corporation. Annual report on Form 10-K for the fiscal year ended 31 October 2005. Filed 17 January 2006. SEC archive. Available online: https://www.sec.gov/Archives/edgar/data/815508/000095013506000184/b58592bce10vk.htm.
- Office of the Secretary of Defense. Fiscal Year 2008 Research Development Test and Evaluation Budget Item Justification, Defense Acquisition Challenge Program, PE 0604051D8Z, Project P051, Exhibit R-2A, February 2007, RESUS entry on printed page 14 of 31. Available online: https://comptroller.war.gov/portals/45/documents/defbudget/fy2008/budget_justification/pdfs/03_rdt_and_e/vol_3_osd/ba-5.pdf.
- Food and Drug Administration. Blood Products Advisory Committee notice of meeting FR Doc E6-20265. Fed. Regist. 2006, 71(230), 69211. Available online: https://www.federalregister.gov/documents/2006/11/30/E6-20265/blood-products-advisory-committee-notice-of-meeting.
- Biopure Corporation. First quarter financial results and clinical development update, 15 February 2007. Available online: https://www.sec.gov/Archives/edgar/data/815508/000095013507000908/b64208bcexv99w1.htm.
- Biopure Corporation. Letter to stockholders, friends and employees, 25 July 2007. SEC-filed exhibit. Available online: https://www.sec.gov/Archives/edgar/data/815508/000095013507004430/b66256bcexv99w1.htm.
- Biopure Corporation. Third quarter financial results and U.S. Navy program update, 23 August 2007. Available online: https://www.sec.gov/Archives/edgar/data/815508/000095013507005269/b66691bcexv99w1.htm.
- Biopure Corporation. Annual report on Form 10-K for the fiscal year ended 31 October 2007. Filed 29 January 2008. SEC archive. Available online: https://www.sec.gov/Archives/edgar/data/815508/000095013508000384/b68316bce10vk.htm.
- Biopure Corporation. Current report on Form 8-K, dated 21 November 2008, describing three proposed U.S. Navy protocols and combination-product shipments. SEC archive. Available online: https://www.sec.gov/Archives/edgar/data/815508/000119312508240629/d8k.htm.
- Rausch, C.W.; Jaliashvili, A. Precision Oxygen Therapeutics: From Blood Substitutes to the Biological Hemoglobin Oxygen Carrier (BHOC) Framework for Controlled Microvascular and Tissue-Level Oxygen Delivery. 2026. [Google Scholar] [CrossRef]
| Date | Record | Documented status and limit |
|---|---|---|
| 2003 | Signed NMRC–Biopure CRADA; planned trial and contribution schedule [1]. | Agreement executed; human trial and projected spending unverified. |
| 2005 | Amendment 3; written-request condition for 1,500 units at an estimated cost ceiling of $650 each [1]. | Contingency term; no documented trigger, invoice or field delivery. |
| 2005 | NMRC IND submitted in June; July FDA clinical hold reported in 10-K and DoD justification [2,3]. | Application filed; study under hold, without permission to start as submitted. |
| 2006 | FDA committee meeting notice; 11–8 vote with one abstention reported by Biopure [4,5,8]. | Review and company-reported recommendation; no trial approval. |
| 2007 | Revised Phase 2 protocol submitted; Biopure reported continuing hold [6,7,8]. | New submission; no RESUS enrollment shown in the examined records. |
| 2007 | DoD project line $0.332m, fiscal 2006, Air Force lead; Navy preclinical buy agreement [3,8]. | Different budget and purchase categories; no basis to merge totals or infer field use. |
| 2008 | Three future protocol submissions expected; combination products described as shipped [9]. | Plans and some research shipments; quantities and clinical use unspecified. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.